# Neoantigen Derived DCs as Cancer Treatment

> **NCT05767684** · PHASE1 · UNKNOWN · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 12 (estimated)

## Conditions studied

- Refractory Tumor
- Solid Tumor

## Interventions

- **BIOLOGICAL:** Dendritic Cell Vaccine
- **DRUG:** Lenvatinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05767684
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05767684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05767684, "Neoantigen Derived DCs as Cancer Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05767684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*